Fusion Antibodies PLC

Fusion Antibodies operates with a fully diluted share count of 125,021,878 shares, with no difference between basic and diluted shares outstanding, indicating no immediate dilution risk from stock options or convertible instruments. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. Profitability metrics are not available for direct comparison to industry medians, as the valuation snapshot contains no computed ratios. Analyst estimates indicate a continued loss per share, with a mean EPS estimate of -0.01 GBP and a last actual EPS of -0.02 GBP. EBIT estimates also show a loss of -864,000 GBP, suggesting ongoing operational challenges. The company's revenue is concentrated in undisclosed segments and geographic regions, as no segment or geographic breakdown is provided in the available data. This lack of transparency limits the ability to assess exposure to specific markets or product lines. Growth trajectory appears modest, with last actual revenue at 1,965,000 GBP and a mean revenue estimate of 2,255,000 GBP, indicating a potential year-over-year increase of 14.7%. However, the absence of multi-year revenue history prevents a more robust growth assessment. Risk factors include the lack of liquidity assessment and ongoing losses, which could impact the company's ability to fund operations without external financing. Dilution risk is currently low, but the absence of balance-sheet data means this could change rapidly with new financing rounds. Recent events include the publication of analyst estimates for EPS and revenue, but no specific filings or transcripts are available in the current dataset to provide further insight into management guidance or strategic direction.